RxDoctor Payments DataLook up a doctor →

Craig Zaidman, MD

Neurology with Special Qualifications in Child Neurology · Saint Louis, MONPI 1447450507

Payments from drug & device makers

$9,806,032in general payments, 2019–2025

Across 2,188 payments — averaging $4481.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3.9M
  • Sarepta Therapeutics, Inc.$3.9M
  • Amicus Therapeutics, Inc.$639K
  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$354K
  • NS Pharma, Inc.$340K
  • Novartis$310K
  • plus $324K from 11 others
$11,277in research payments, 2019–2025

Across 18 payments — averaging $626.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sarepta Therapeutics, Inc.$6K
  • F. Hoffmann-la Roche AG$4K
  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$2K

What the payments were for

  • Consulting fees$56,20851%
  • Speaking & faculty fees$11,31710%
  • Travel & lodging$12,94812%
  • Food & beverage$1,2071%
  • Education$28,67626%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,806,032 in reported general payments places this provider in the 95th percentile of 41 neurology with special qualifications in child neurology providers in Missouri.

See all neurology with special qualifications in child neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$42,212
Medicare patients
151
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam16$431,955
Clonidine Hcl13$30

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →